U.S. markets closed

Candel Therapeutics, Inc. (CADL)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
1.7600+0.0400 (+2.33%)
At close: 03:58PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Relative Strength Index (RSI)

Relative Strength Index (RSI)

Previous Close1.7200
Bid1.6200 x 2900
Ask1.8600 x 1000
Day's Range1.6200 - 1.7650
52 Week Range0.6600 - 2.3000
Avg. Volume618,505
Market Cap50.899M
Beta (5Y Monthly)0.74
PE Ratio (TTM)N/A
EPS (TTM)-1.1000
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est9.50
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for CADL

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Candel Therapeutics, Inc.
    Daily – Vickers Top Insider Picks for 03/08/2023The Vickers Top Insider Picks is a daily report that utilizes a proprietary algorithm to identify 25 companies with compelling insider purchase histories based on transactions over the past three months.
    Fair Value
    Economic Moat
    last yearArgus Research
View more
  • GlobeNewswire

    CAN-3110 Receives FDA Fast Track Designation for Treatment of Recurrent High-Grade Glioma

    NEEDHAM, Mass., Feb. 13, 2024 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced that the U.S. Food and Drug Administration (FDA) granted Fast Track Designation for CAN-3110 -- a first-in-class, replication-competent herpes simplex virus-1 (HSV-1) oncolytic viral immunotherapy candidate – for the treatment of pati

  • GlobeNewswire

    Candel Therapeutics Sets Path to Success: Recent Achievements Pave the Way for a Promising 2024 Propelled by Key Value Drivers and Catalysts

    Approaching 6 anticipated data readouts across 3 platforms in 2024, including survival data in non-small cell lung cancer (NSCLC) and a potentially registrational phase 3 clinical trial in prostate cancerFocusing on strategic key value drivers and catalysts, as a follow up to positive initial clinical and biomarker data in hard-to-treat cancersAdvancing the immunotherapy field with next-generation investigational therapies at the intersection of advanced analytics, biology and vectorologyExecuti

  • Zacks

    Candel (CADL) Rises on FDA's Fast Track Status for CAN-2409

    The FDA gives Fast Track designation to Candel's (CADL) lead candidate, CAN-2409 plus prodrug (valacyclovir), for the treatment of patients with pancreatic cancer.